AU3544599A - Use of radiolabeled monoclonal igm in therapy for cancer and autoimmune disease - Google Patents
Use of radiolabeled monoclonal igm in therapy for cancer and autoimmune diseaseInfo
- Publication number
- AU3544599A AU3544599A AU35445/99A AU3544599A AU3544599A AU 3544599 A AU3544599 A AU 3544599A AU 35445/99 A AU35445/99 A AU 35445/99A AU 3544599 A AU3544599 A AU 3544599A AU 3544599 A AU3544599 A AU 3544599A
- Authority
- AU
- Australia
- Prior art keywords
- cancer
- therapy
- autoimmune disease
- monoclonal igm
- radiolabeled monoclonal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US862098A | 1998-01-16 | 1998-01-16 | |
US09008620 | 1998-01-16 | ||
PCT/US1999/000857 WO1999036105A2 (en) | 1998-01-16 | 1999-01-15 | USE OF RADIOLABELED MONOCLONAL IgM IN THERAPY FOR CANCER AND AUTOIMMUNE DISEASE |
Publications (1)
Publication Number | Publication Date |
---|---|
AU3544599A true AU3544599A (en) | 1999-08-02 |
Family
ID=21732655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU35445/99A Abandoned AU3544599A (en) | 1998-01-16 | 1999-01-15 | Use of radiolabeled monoclonal igm in therapy for cancer and autoimmune disease |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1047457A2 (en) |
JP (1) | JP2002509122A (en) |
AU (1) | AU3544599A (en) |
CA (1) | CA2318231A1 (en) |
WO (1) | WO1999036105A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1373321A2 (en) * | 2001-01-29 | 2004-01-02 | Idec Pharmaceuticals Corporation | Modified antibodies and methods of use |
US7319139B2 (en) | 2001-01-29 | 2008-01-15 | Biogen Idec, Inc. | TAG-72 specific CH2 domain deleted antibodies |
DE602004030451D1 (en) | 2003-07-15 | 2011-01-20 | Chugai Pharmaceutical Co Ltd | PRODUCTION OF IGM BY TRANSFORMED CELLS AND METHOD FOR QUANTIFYING THIS IGM PRODUCTION |
EP1688432B1 (en) | 2003-10-09 | 2011-08-03 | Chugai Seiyaku Kabushiki Kaisha | Igm high concentration stabilized solution |
US20060127311A1 (en) * | 2004-11-17 | 2006-06-15 | Duke University | Radiation dosimetry and blocking antibodies and methods and uses therefor in the treatment of cancer |
US8193145B2 (en) * | 2007-10-09 | 2012-06-05 | Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno | Laminins, derivatives, and compositions including same and methods for their therapeutic use |
KR102289054B1 (en) * | 2019-03-29 | 2021-08-19 | 한국수력원자력 주식회사 | Prevention of rheumatoid arthritis by low-dose ionizing radiation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5292868A (en) * | 1989-05-26 | 1994-03-08 | Akzo N.V. | Chelating agents for attaching metal ions to proteins |
DK0429624T3 (en) * | 1989-06-19 | 1994-05-30 | Akzo Nobel Nv | Radioimmunotherapy using alpha particle emission |
US5578289A (en) * | 1992-03-04 | 1996-11-26 | Akzo N.V. | In vivo binding pair pretargeting |
JP4124486B2 (en) * | 1996-05-22 | 2008-07-23 | ビベンティア バイオテック インコーポレイテッド | Antigen binding fragment that specifically detects cancer cells, nucleotides encoding this fragment, and use thereof for cancer prevention and detection |
-
1999
- 1999-01-15 JP JP2000539876A patent/JP2002509122A/en not_active Withdrawn
- 1999-01-15 AU AU35445/99A patent/AU3544599A/en not_active Abandoned
- 1999-01-15 WO PCT/US1999/000857 patent/WO1999036105A2/en not_active Application Discontinuation
- 1999-01-15 EP EP99917293A patent/EP1047457A2/en not_active Withdrawn
- 1999-01-15 CA CA002318231A patent/CA2318231A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2318231A1 (en) | 1999-07-22 |
WO1999036105A2 (en) | 1999-07-22 |
JP2002509122A (en) | 2002-03-26 |
WO1999036105A9 (en) | 1999-10-21 |
WO1999036105A3 (en) | 2000-02-10 |
EP1047457A2 (en) | 2000-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL131539A0 (en) | Compounds for immunodiagnosis of prostate cancer and methods for their use | |
IL136335A0 (en) | Monoclonal human natural antibodies | |
HK1096974A1 (en) | Antibody against human parathormone related peptides | |
AU1462300A (en) | Human pan-hcv human monoclonal antibodies | |
IL117725A0 (en) | Radiolabeled peptides for diagnosis and therapy | |
AU5536196A (en) | Cancer diagnosis and therapy based on mutations in tgf-beta receptors | |
AU1810899A (en) | Neuropilins and use thereof in methods for diagnosis and prognosis of cancer | |
AU7676300A (en) | Human anti-adipocyte monoclonal antibodies and their use | |
EP0831793A4 (en) | Protein particles for therapeutic and diagnostic use | |
EP1178829A4 (en) | Human monoclonal antibody | |
HK1063004A1 (en) | Oxalatoplatin and 5-fluorouracil for combination therapy of cancer | |
AU3544599A (en) | Use of radiolabeled monoclonal igm in therapy for cancer and autoimmune disease | |
GB9811598D0 (en) | Diagnosis and treatment of cancer | |
PL325457A1 (en) | Humanised antibodies effective against human fas | |
EP0977590A4 (en) | Human monoclonal antibodies | |
ZA9510195B (en) | Monoclonal antibody fragments having immunosuppressant activity | |
NZ501742A (en) | Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10 | |
AU6111800A (en) | 26 human prostate and prostate cancer associated proteins | |
ZA9810974B (en) | Conjugates useful in the treatment of prostate cancer | |
GB9812550D0 (en) | Tumour therapy and imaging | |
AU4499196A (en) | Antibodies for use in cancer therapy and diagnosis | |
SI1157041T1 (en) | Antibodies for cancer therapy and diagnosis | |
AU5279996A (en) | Antibodies and their use in cancer therapy and diagnosis | |
GB9828564D0 (en) | Materials and methods for the treatment and diagnosis of cancer | |
GB9621093D0 (en) | Antigen for use in cancer therapy and diagnosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |